|Podcasts|November 24, 2022

Tuning Into CTV - Real Time Data For Marketers

In this episode, Marcella Milliet Sciorra, Chief Marketing Officer at DeepIntent, discusses Connected TV, or CTV, how it differs from over the top, and how CTV fits into the future of pharmaceutical marketing.

Senior Editor, Fran Pollaro, also talks to Milliet Sciorra about:

  • CTV being one of the hottest marketing channels available today
  • The role of TV today for pharma and patient perception
  • Pharma marketer hesitancy
  • What data tell us about the overall CTV landscape, CTV audiences, and their viewing preferences

About the Pharm Exec Podcast

The editors of Pharmaceutical Executive bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.

Listen to this podcast on SoundCloudSpotifyGoogle Podcasts, or Apple Podcasts.


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Pharmaceutical Executive daily
FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis Medicines, Dualitas Therapeutics, and North Immunology, and Thani Jambulingam of Saint Joseph's University examines the fight to control the GLP-1 patient journey.
Pharmaceutical executive daily
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.